| Literature DB >> 29735963 |
Zhengqin Qi1, Yan Pang2, Lin Lin3, Bing Zhang1, Juntao Shao1, Xiaodong Liu1, Xin Zhang4.
Abstract
BACKGROUND The aim of this pragmatic study was to explore the intervention of acupuncture combined with hydrotherapy and perceived effects in type 2 diabetic patients with recently diagnosed, mild, lower-extremity arterial disease (LEAD) in comparison with a control group. MATERIAL AND METHODS One hundred twenty-six diabetes patients who were diagnosed mild LEAD according to ankle-brachial blood pressure index (ABPI) and peripheral neuropathy symptom were randomly assigned to either an experimental (n=64) or control group (n=62). The experimental group attended and completed (1) a 30-min session of acupuncture in certain selected points, and (2) a 30-min hydrotherapy exercise every 2 days for 15 weeks. The outcome parameters were assessed at baseline, after intervention, and at 6-week follow-up. RESULTS The intervention was associated with an improvement in leg flow conductance and partial physical capacities, including chair-sit-and-reach, the walking impairment questionnaire (WIQ), and physical component summary score (PCS), compared to the control group. The treatment benefits were sustained throughout the 6-week follow-up endpoint. There was no difference in fasting glucose levels, Hb1Ac, blood pressure, or BMI after the intervention. At the endpoint of 6-week follow-up, acupuncture plus hydrotherapy appeared to reduce inflammatory response by decreasing IL-6, TNF-α, malondialdehyde, and SOD, and increasing glutathione. CONCLUSIONS Acupuncture plus hydrotherapy, without significant glycemic-controlling effects in the type 2 diabetic patients with mild LEAD, exerts a measurable benefit in disease-specific physical functions and health-related quality of life. Our results suggest that the combined therapy regulates the inflammatory process and oxidative stress and contributes to immune protection.Entities:
Keywords: Acupuncture; Hydrotherapy; Lower-Extremity Arterial Disease; Oxidative Stress; diabetes; inflammatory
Mesh:
Substances:
Year: 2018 PMID: 29735963 PMCID: PMC5963737 DOI: 10.12659/MSM.909733
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
The basic characteristics of the concentrations of main materials in the hydrotherapy.
| Main components | Levels |
|---|---|
| Temperature (°C) | 65 (2) |
| pH value | 7.8 (0.9) |
| TDS (mg/L) | 1599 (144) |
| Na+ (mg/L) | 354.7 (21.5) |
| K+ (mg/L) | 2.98 (0.11) |
| Mg+ (mg/L) | 5.60 (0.42) |
| Ca2+ (mg/L) | 8.92 (1.52) |
| SiO4 (mg/L) | 34.3 (2.8) |
| Cl− (mg/L) | 107.1 (9.3) |
| HCO3 2− (mg/L) | 1085.3 (95.2) |
| SO42− (mg/L) | 87.9 (9.3) |
| Radon (Bq/m3) | 127 (11.6) |
| Br− (mg/L) | 38.2 (4.9) |
| Fe2+ (mg/L) | 19.1 (2.2) |
| Sr (mg/L) | 35.3 (4.8) |
| Li (mg/L) | 1.29 (0.09) |
| Mn (mg/L) | 1.55 (0.12) |
| BHBO2 | 1.24 (0.11) |
| Conductivity (μS/cm) | 1907 (122) |
Data are means (SD); TDS – total dissolved solids.
Baseline characteristics of study groups.
| Characteristics | Intervention (N=64) | Control (N=62) |
|---|---|---|
| Age (yrs.) | 60.4 (8.3) | 60.1 (8.9) |
| Female (%) | 49 | 54 |
| Duration of diabetes (years) | 9.8 (1.9) | 9.4 (2.0) |
| Fasting glucose (mg/dl) | 176.5 (20.7) | 162.3 (21.2) |
| Insulin (μIU/ml) | 42.8 (7.9) | 45.8 (8.2) |
| ABPI | 0.78 (0.15) | 0.74 (0.17) |
| Duration of LEAD (years) | 1.1 (0.2) | 0.9 (0.2) |
| Oral hypoglycemic drugs (%) | 11.9 | 9.4 |
| Oral hypoglycemic and insulin (%) | 88.1 | 90.6 |
| Anthropometric measures | ||
| Waist circumference (cm) | 95.6 (12.3) | 98.5 (11.9) |
| Waist-to-Hip Ratio | 0.75 (0.81) | 0.74 (0.87) |
| BMI | 30.8 (4.1) | 31.2 (4.2) |
| Lower-body flexibility | −4.91 (0.45) | −4.64 (0.38) |
| Hip joint flexibility | 79.6 (8.1) | 83.7 (8.6) |
| Lower-body strength and endurance | 12.9 (1.4) | 13.1 (1.7) |
| β-blockers | 88.5 | 89.1 |
| RAS blockers | 91.5 | 93.9 |
| Calcium channel blockers | 56.3 | 49.7 |
| Antifibrinolytic use | 56.1 | 55.8 |
| Lipid-modifying agent | 59.1 | 61.2 |
| Smoking | ||
| Current | 2.3 | 1.9 |
| Previous | 54.2 | 60.3 |
| Never | 43.5 | 37.8 |
| Alcohol drinking | ||
| Current | 1.1 | 1.0 |
| previous | 59.9 | 60.5 |
| Never | 39.0 | 38.5 |
| Hypertension | 59.9 | 57.2 |
| Serum TG | 45.6 | 41.8 |
| Serum LDL-C | 56.9 | 60.7 |
| Arthritis in lower extremity | 3.7 | 2.9 |
| Respiratory disease | 15.9 | 19.1 |
| Renal dysfunction | 25.7 | 31.6 |
| Coronary artery disease | 42.9 | 41.5 |
| Hepatic disease | 3.1 | 3.4 |
Acupuncture plus hydrotherapy; Data are means (SD) or n (% percentage); ABPI – ankle-brachial pressure index;
represents angiotensin-converting enzyme inhibitors and angiotensin receptor blockers;
TG – total glyceride, LDL-C – low-density lipoprotein cholesterol;
glomerular filtration rate (GFR) ≤60 ml/min/1.73 m2.
The main outcomes in baseline, post-15-week acupuncture plus hydrotherapy, and 6-week follow-up periods.
| Parameter | Acupuncture+Hydrotherapy | Control | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | intervention | Follow-up | Baseline | intervention | Follow-up | |||
| Fasting glucose (mg/dl) | 176.5 (20.7) | 170.1 (18.2) | 170.9 (19.8) | 0.31 | 162.3 (21.2) | 160.1 (20.7) | 161.7 (22.9) | 0.31 |
| Insulin (uIU/ml) | 42.8 (7.9) | 40.4 (6.9) | 42.0 (7.8) | 0.27 | 45.8 (8.2) | 40.1 (8.9) | 40.7 (6.7) | 0.24 |
| HbA1C | 6.8 (1.3) | 6.9 (1.6) | 6.9 (1.8) | 0.31 | 7.0 (1.4) | 6.7 (1.4) | 6.7 (1.6) | 0.21 |
| C-reactive protein (mg/dl) | 15.2 (3.3) | 15.9 (3.2) | 15.7 (3.5) | 0.29 | 16.6 (3.5) | 15.9 (3.2) | 16.9 (3.4) | 0.32 |
| Interleukin (IL)-6 (pg/ml) | 1.39 (0.19) | 1.32 (0.17) | 1.27 (0.20) | 0.11 | 1.32 (0.22) | 1.39 (0.29) | 1.37 (0.24) | 0.21 |
| (TNF)-α (pg/ml) | 0.66 (0.05) | 0.60 (0.06) | 0.62 (0.05) | 0.14 | 0.63 (0.07) | 0.67 (0.05) | 0.69 (0.07) | 0.17 |
| MDA (μmol/l) | 2.79 (0.81) | 2.33 (0.73) | 2.30 (0.74) | 0.10 | 2.85 (0.80) | 2.84 (0.81) | 2.81 (0.77) | 0.13 |
| SOD (U/ml) | 1.75 (0.37) | 1.59 (0.38) | 1.60 (0.39) | 0.09 | 1.79 (0.32) | 1.78 (0.35) | 1.80 (0.33) | 0.17 |
| GSH (μmol/l) | 1.92 (0.46) | 2.07 (0.50) | 2.19 (0.44) | 0.09 | 2.00 (0.42) | 1.98 (0.36) | 2.02 (0.35) | 0.16 |
| ABPI | 0.78 (0.15) | 0.82 (0.19) | 0.81 (0.19) | 0.06 | 0.74 (0.17) | 0.73 (0.18) | 0.73 (0.20) | 0.09 |
| Leg vascular conductance (ml//min/mm Hg) | 3.03 (4.2) | 3.64 (4.2) | 3.67 (4.1) | <0.05 | 3.02 (4.3) | 3.31 (4.5) | 3.10 (4.6) | 0.07 |
| Blood pressure (mmHg) | ||||||||
| Systolic | 159.3 (17.3) | 161.4 (18.2) | 160.8 (17.1) | 0.09 | 161.2 (17.8) | 160.7 (17.7) | 161.9 (18.1) | 0.10 |
| Diastolic | 91.9 (10.3) | 92.0 (10.9) | 92.4 (11.1) | 0.09 | 92.2 (10.1) | 92.6 (11.7) | 93.7 (10.9) | 0.09 |
| Lower-body flexibility, median (IQR) | ||||||||
| Chair-sit-and-reach | −5.99 (−3.51, −9.96) | −5.35 (−3.43, −9.37) | −5.82 (−3.89, −9.11) | 0.09 | −5.47 (−3.25, −8.79) | −5.49 (−3.30, −9.01) | −5.16 (−3.09, −8.19) | 0.15 |
| Hip joint flexibility | 78.9 (46.3, 128.8) | 80.9 (49.7, 134.6) | 83.7 (48.8, 134.9) | 0.07 | 79.8 (48.5, 132.8) | 79.9 (48.1, 146.3) | 77.9 (46.8, 140.9) | 0.21 |
| Strength/endurance | 10.5 (6.2, 19.1) | 11.9 (7.2, 21.8) | 12.7 (8.2, 23.5) | 0.04 | 11.0 (6.6, 19.6) | 10.9 (6.5, 18.4) | 10.9 (6.6, 19.1) | 0.41 |
| Aerobic walking endurance | ||||||||
| 4-M walking speed (m/sec) | 0.79 (0.11) | 0.84 (0.12) | 0.82 (0.15) | 0.07 | 0.81 (0.12) | 0.80 (0.14) | 0.79 (0.14) | 0.18 |
| WIQ distance score (0–100 scale) | 30.1 (18.2, 54.2) | 32.8 (20.3, 54.4) | 32.3 (22.2, 51.5) | 0.04 | 31.7 (19.2, 54.9) | 32.2 (19.6, 54.1) | 31.9 (18.6, 54.7) | 0.11 |
| WIQ speed score (0–100 scale) | 34.7 (20.2, 54.6) | 34.9 (21.1, 61.3) | 34.9 (22.2, 61.0) | 0.08 | 33.8 (19.8, 59.6) | 33.8 (19.4, 59.3) | 33.5 (19.0, 58.8) | 0.18 |
| EQ-5D dimension problems (%) | 21.4 | 22.2 | 21.9 | 0.06 | 22.0 | 21.5 | 21.9 | 0.11 |
| EQ-5D index (0–1) score, median (IQR) | 0.57 (0.35, 1.12) | 0.64 (0.38, 1.17) | 0.69 (0.41, 1.28) | 0.04 | 0.57 (0.34, 1.04) | 0.54 (0.31, 0.99) | 0.53 (0.30, 0.97) | 0.11 |
| SF-12, media (IQR) | ||||||||
| PCS | 30.7 (18.6, 54.5) | 35.8 (23.9, 72.1) | 36.3 (24.2, 73.3) | 0.03 | 31.3 (18.7, 55.3) | 30.9 (19.9, 55.1) | 32.9 (19.8, 56.8) | 0.27 |
| MCS | 42.8 (25.6, 74.8) | 49.7 (29.8, 90.4) | 51.7 (31.4, 93.8) | <0.05 | 42.1 (25.2, 75.5) | 43.2 (25.9, 75.8) | 43.7 (26.2, 78.9) | 0.07 |
Data are means (SD) or n (%, percentage) or interquartile range (IQR);.
a linear trend value.
TNF – tumor necrosis factor; MDA – malondialdehyde; SOD – superoxide dismutase; GSH – reduced glutathione; WIQ – the walking impairment questionnaire; PCS – the physical component summary score; MCS – mental health component summary score.
Results of variables post-intervention group and follow-up vs. control group.
| Outcome | 15-week intervention | 6-week Follow-up | ||||
|---|---|---|---|---|---|---|
| Difference (Cl 95%) | ES (Cl 95%) | p | Difference (Cl 95%) | ES (Cl 95%) | p | |
| C-reactive protein | 1.40 (0.3, 2.6) | 0.31 (0.26, 0.36) | 0.07 | 0.20 (−0.09, 3.5) | 0.11 (0.06, 0.16) | 0.15 |
| IL-6 | −0.14 (−0.03, −0.26) | 0.32 (0.28, 0.36) | 0.06 | −0.17 (−0.09, −0.28) | 0.50 (0.45, 0.55) | <0.05 |
| TNF-α | −0.13 (−0.06, −0.21) | 0.52 (0.46, 0.59) | <0.05 | −0.13 (−0.06, −0.21) | 0.52 (0.46, 0.59) | <0.05 |
| MDA | −0.45 (−0.21, −0.69) | 0.44 (0.29, 0.59) | <0.05 | −0.45 (−0.22, −0.69) | 0.41 (0.30, 0.53) | <0.05 |
| SOD | −0.15 (−0.06, −0.24) | 0.35 (0.29, 0.41) | 0.05 | −0.16 (−0.05, −0.27) | 0.38 (0.26, 0.51) | <0.05 |
| GSH | 0.13 (0.4, 0.23) | 0.27 (0.11, 0.42) | 0.09 | 0.25 (0.12, 0.38) | 0.43 (0.17, 0.69) | <0.05 |
| ABPI | 0.05 (0.01, 0.09) | 0.38 (0.10, 0.66) | <0.05 | 0.04 (0.008,0.072) | 0.32 (0.09, 0.55) | <0.05 |
| ECQ (%) | ||||||
| Grade 1 | 7.5 (1.2, 13.8) | 0.54 (0.10, 0.98) | <0.05 | 9.0 (1.5, 16.5) | 0.49 (0.14, 0.84) | <0.02 |
| Grade 2 | −7.4 (−1.1, −13.7) | 0.55 (0.10, 1.0) | <0.02 | −9.0 (−1.4, −16.6) | 0.58 (0.14, 1.02) | <0.02 |
| Leg vascular conductance | 0.32 (0.08, 0.56) | 0.43 (0.14, 0.72) | <0.02 | 0.56 (0.13, 0.99) | 0.59 (0.19, 0.99) | <0.01 |
| Systolic | 2.60 (0.9, 4.3) | 0.28 (0.04, 0.52) | 0.15 | 0.80 (0.2, 1.4) | 0.10 (0.02, 0.18) | 0.25 |
| Diastolic | −0.3 (0.09, −0.51) | 0.12 (0.01, 0.23) | 0.24 | −1.0 (0.25, −1.75) | 0.09 (0.01, 0.17) | 0.29 |
| Chair-sit-and-reach | 1.08 (0.9, 2.08) | 0.53 (0.22, 0.84) | <0.02 | 0.88 (0.2, 1.59) | 0.49 (0.22, 0.74) | <0.05 |
| Hip joint flexibility | 3.9 (0.3, 7.6) | 0.19 (0.12–0.27) | 0.10 | 17.1 (1.4, 33.2) | 0.51 (0.45–0.57) | <0.05 |
| Strength/endurance | 2.8 (1.1, 4.8) | 0.52 (0.27, 0.77) | <0.02 | 3.5 (1.3, 5.9) | 0.55 (0.36, 0.74) | <0.01 |
| 4-M walking speed | 0.06 (−0.7, 0.11) | 0.38 (0.32, 0.44) | 0.06 | 0.05 (−0.8, 0.10) | 0.20 (0.15, 0.25) | 0.08 |
| WIQ distance score | 7.7 (0.7, 14.8) | 0.53 (0.46, 0.60) | <0.05 | 11.0 (1.3–21.9) | 0.65 (0.59, 0.71) | <0.02 |
| WIQ speed score | 4.7 (0.6, 9.1) | 0.50 (0.42, 0.58) | <0.05 | 4.7 (0.6–9.1) | 0.50 (0.42, 0.58) | <0.05 |
| EQ-5D index score | 0.10 (0.02, 0.19) | 0.50 (0.43–0.57) | <0.05 | 0.16 (0.04, 0.31) | 0.52 (0.46–0.58) | <0.05 |
| SF-12 | ||||||
| PCS | 5.5 (1.2, 9.8) | 0.57 (0.74, 0.94) | 0.01 | 4.0 (0.5, 7.5) | 0.51 (0.22, 0.80) | <0.05 |
| MCS | 6.0 (0.2, 11.8) | 0.22 (0.17, 0.27) | 0.08 | 7.5 (0.3, 15.5) | 0.33 (0.27, 0.39) | 0.06 |
% – percentage; IL – interleukin; TNF – tumor necrosis factor; ES – effect size; additional definitions refer to Table 3.
Association of TNF-α, MDA, SOD, and GSH levels with outcomes in the acupuncture plus hydrotherapy intervention and follow-up in diabetics with mild LEAD.
| Outcome | TNF-α | MND | SOD | GSH | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |||||
| LVC | 0.58 | 0.42–0.78 | 0.02 | 0.69 | 0.52–0.93 | 0.01 | 0.74 | 0.57–0.96 | 0.01 | 1.28 | 1.03–1.64 | 0.005 |
| Chair-sit-and-reach | 0.54 | 0.41–0.75 | 0.005 | 0.61 | 0.48–0.84 | 0.008 | 0.72 | 0.66–0.90 | 0.009 | 1.22 | 1.05–1.69 | 0.009 |
| Strength/endurance | 0.49 | 0.44–0.70 | 0.004 | 0.55 | 0.43–0.69 | 0.004 | 0.76 | 0.69–0.89 | 0.02 | 1.21 | 1.06–1.69 | 0.011 |
| WIQ | 0.56 | 0.43–0.69 | 0.009 | 0.66 | 0.56–0.79 | 0.01 | 0.81 | 0.73–0.96 | 0.04 | 1.27 | 1.03–1.66 | 0.004 |
| PCS | 0.51 | 0.40–0.66 | 0.001 | 0.61 | 0.45–0.81 | 0.007 | 0.88 | 0.71–0.99 | 0.04 | 1.22 | 1.06–1.62 | 0.008 |
Adjusted for age, sex.
Treatment, medical history and other factors. OR – odds ratio; CI – confidence interval; LVC – leg vascular conductance. Additional definitions refer to Table 3.